Kontakt aufnehmen

Bitte kontaktieren Sie uns, wenn Sie weitere Fragen zu DUROLANE haben.

+WPharma GmbH
Anton Anderer – Platz 6 / Top 1
A-1210 Wien

 

Contact 

Email: info@pluswpharma.com
T: +43 (0) 664 84 62 631
F: +43 1 25 33 03 32 160

www.pluswpharma.com

Summary of Indications for Use

DUROLANE (3 mL): Argentina, Australia,* Brazil, Chile, Colombia, EU,* India, New Zealand,* Russia, Switzerland,* Turkey,* United Arab Emirates: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in Australia, EU and New Zealand for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

Mexico: Symptomatic treatment of mild to moderate knee osteoarthritis.

Taiwan: Treatment of pain in OA of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. In addition, DUROLANE has been licensed for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

*DUROLANE is also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

Full prescribing information can be found in product labeling.

Summary of risks: You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/ or stiffness at the injection site.

Full prescribing information can be found on the product labeling.

Summary of Indications for Use for Curavisc: Curavisc (2 mL): EU, Brazil, Egypt, Malaysia: Pain and disturbed function in degenerative and traumatic disease of the joints. Curavisc can be used for large joints, e.g., knee, hip, or shoulder joint. Treatment course of 3- injections, up to 5- injections.

Summary of risks: You should not use CURAVISC if you have infections or skin disease at the injection site. CURAVSIC has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/ or stiffness at the injection site.

Full prescribing information can be found on the product labeling and on the website at bioventus.com/curavisc.com.